Analytical Data
-
Gene name
IFNa9
- Application
-
Species
Mouse
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P09235
-
Expression Region
Cys22~Glu188
-
Molecular Weight
22/20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon alpha 9 (IFNa9) is a member of the type I interferon family, which plays a crucial role in the immune response against viral infections and has potential therapeutic applications in oncology and autoimmune diseases. Research has identified IFNa9's unique properties compared to other interferons, highlighting its specific antiviral and immunomodulatory effects. The administration of IFNa9 can enhance the activation of immune cells, promoting a robust antiviral response and potentially inhibiting tumor growth. Furthermore, its lower side effect profile compared to other interferons has made it an attractive candidate for further investigation. Recent studies focus on the molecular mechanisms underlying IFNa9's action, including its ability to modulate gene expression and affect various signaling pathways. Additionally, recombinant technology has enabled the production of IFNa9 in significant quantities, facilitating both in vitro and in vivo studies. As researchers delve deeper into its therapeutic potential, understanding the precise mechanisms of IFNa9 could lead to novel treatment strategies for viral infections, cancer, and inflammatory disorders, offering hope for improved clinical outcomes.
